Amylyx Pharmaceuticals, Inc. Shareholders' Equity
Amylyx Pharmaceuticals, Inc. (AMLX) had Shareholders' Equity of $239.17 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-06
- 2026-06-30: Stockholders' Equity Attributable to Parent $239.17M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $273.16M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $305.26M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $332.00M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $239.17M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $273.16M 10-Q · filed 2026-08-06 |
| 2025-12-31 | $305.26M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $332.00M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $167.88M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $201.42M 10-Q · filed 2026-08-06 |
| 2024-12-31 | $164.76M 10-Q · filed 2026-08-06 |
| 2024-09-30 | $196.20M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $261.31M 10-Q · filed 2025-11-06 |
| 2024-03-31 | $324.44M 10-Q · filed 2025-11-06 |
| 2023-12-31 | $433.43M 10-K · filed 2026-03-03 |
| 2023-09-30 | $418.40M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $386.37M 10-Q · filed 2024-11-07 |
| 2023-03-31 | $352.65M 10-Q · filed 2024-11-07 |
| 2022-12-31 | $340.61M 10-K · filed 2025-03-04 |
| 2022-09-30 | $144.03M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $192.79M 10-Q · filed 2023-11-09 |
| 2022-03-31 | $240.95M 10-Q · filed 2023-11-09 |
| 2021-12-31 | -$151.17M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$124.07M 10-Q · filed 2022-11-10 |
| 2021-06-30 | -$101.89M 10-Q · filed 2022-11-10 |
| 2021-03-31 | -$80.63M 10-Q · filed 2022-11-10 |
| 2020-12-31 | -$66.72M 10-K · filed 2024-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |